Adaptimmune Therapeutics PLC - ESG Rating & Company Profile powered by AI
This SDG score for Adaptimmune Therapeutics PLC represents its transparency towards the United Nations Sustainable Development Goals. If you work at Adaptimmune Therapeutics PLC and you wish to licence your ESG rating, please contact us. Alternative companies in the rating industry group for Adaptimmune Therapeutics PLC are displayed.
Adaptimmune Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 4.0, social score of 4.8 and governance score of 8.0.
5.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
| 579 | VIVA Biotech Holdings | 5.7 | High |
| 602 | Adaptimmune Therapeutics PLC | 5.6 | High |
| 602 | Celltrion Inc | 5.6 | High |
| 602 | Aligos Therapeutics Inc | 5.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Adaptimmune Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC report the average age of the workforce?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC offer flexible work?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC conduct supply chain audits?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose water use targets?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Adaptimmune Therapeutics PLC have a product recall in the last two years?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Adaptimmune Therapeutics PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose parental leave metrics?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Adaptimmune Therapeutics PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose its waste policy?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC report according to TCFD requirements?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose energy use targets?
Sign up for free to unlockDoes Adaptimmune Therapeutics PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Adaptimmune Therapeutics PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Adaptimmune Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.